DOCS Doximity, Inc.

A number of stocks jumped in the afternoon session after the Bureau of Economic Analysis reported a 0.9% increase in personal consumption expenditures for August, signaling resilient consumer demand alongside steady economic expansion.

In the latest trading session, Doximity (DOCS) closed at $26.52, marking a +1.22% move from the previous day.

Doximity (DOCS), which calls itself the leading digital platform for U.S. medical professionals, has seen its stock fall steeply over the past year. Even after a rise over the past three months, the shares sit about 65% below their 52-week high. Management continued its repurchase program, allocating approximately $401 million over the latest twelve months. The test is whether it can keep that up through what it calls its AI investment year.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Doximity recently launched Bedside Bench, an open-source benchmark designed to evaluate clinical-grade AI using realistic bedside scenarios, and independent testing by Fireworks ranked its Doximity Ask system ahead of several frontier models. This move highlights how domain-specific, healthcare-focused AI can outperform general-purpose systems on clinically relevant tasks, potentially strengthening Doximity’s positioning as a trusted tool for physicians. We’ll now examine how Doximity’s...

In the closing of the recent trading day, Doximity (DOCS) stood at $26.84, denoting a +2.8% move from the preceding trading day.

Doximity (DOCS) closed at $25.81 in the latest trading session, marking a -2.2% move from the prior day.

NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.

Paul Jorgensen has been ordered to pay the sum in the wake of allegations of insider trading.

SpaceX initiated, Intel upgraded: Wall Street's top analyst calls

Since March 2026, Doximity has been in a holding pattern, posting a small return of 2.8% while floating around $26.41. The stock also fell short of the S&P 500’s 12.1% gain during that period.

A number of stocks jumped in the afternoon session after quarterly earnings and upbeat corporate commentary signaled that artificial intelligence is driving growth across enterprise software rather than threatening legacy business models.

Software is eating the world, and virtually no business is left untouched by it. Companies bringing it to life have been rewarded with explosive earnings growth, and the upward trend shows no signs of stopping as the industry has posted a 44.6% gain over the past six months, beating the S&P 500 by 32.9 percentage points.

DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.

Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.

Doximity stock has had a difficult five year stretch, with shareholders seeing the share price decline 71.8%, even as recent AI driven products have drawn fresh attention. At the current price near US$24.94, the key issue is whether the latest enthusiasm lines up with what the intrinsic value and market based checks say about Doximity. Over five years, the share price decline of 71.8% points to investors reassessing what they are willing to pay for Doximity. Growth expectations around...

Doximity (DOCS) is back in focus after its latest quarterly report showed higher sales, raised full year revenue guidance, and continued margin pressure tied to heavier spending on AI tools. See our latest analysis for Doximity. At a share price of US$24.94, Doximity has seen a 30 day share price return of 15.89% and a 90 day share price return of 25.58%. However, the year to date share price return is down 42.39% and the 1 year total shareholder return is down 60.79%. This points to...

This sale was executed under a pre-established Rule 10b5-1 trading plan adopted in February.

Sitaram's sale was driven by tax obligations from option exercises and RSU vesting, not a shift in conviction.

Restricted stock unit vesting triggered a routine sell-to-cover sale, reducing Zatz's direct holdings by 8% while leaving him with $1.3 million in remaining equity.

This non-discretionary sale tied to restricted stock unit vesting reduced the CFO's direct holdings by 3%, though he retains a $12.1 million equity stake in the healthcare platform operator.

Tangney executed a non-discretionary sale to cover tax withholding on vesting equity awards.

A number of stocks jumped in the afternoon session after the Bureau of Labor Statistics reported that the July Producer Price Index was completely flat month-over-month—coming in below expectations for a 0.2% increase—following the Consumer Price Index print (released earlier in the week) which showed a mild 0.1% monthly increase and an annual inflation rate cooling to 3.4%. Together, the data points suggest price pressures are moderating across both wholesale and consumer levels, taking the urg

Doximity’s second quarter results were met with a notably positive market reaction following revenue that surpassed Wall Street expectations and ongoing momentum in its healthcare professional network. Management attributed the quarter’s growth to increased adoption of AI-powered clinical tools and rising engagement from both hospital and pharmaceutical clients. CEO Jeffrey Tangney highlighted, “Quarterly active workflow prescribers grew more than 30% year-on-year to record highs with nearly hal

Revenue grew 7% as AI adoption accelerated, with AI Scribe users surging 10-fold in July.